Metastatic Lung Non-Small Cell Carcinoma Clinical Trials

21 studies are recruiting for metastatic lung non-small cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner Health- MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

2. Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

   This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT04780568 on ClinicalTrials.gov

3. Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

   This phase I/II trial tests the safety, side effects and best dose of sotorasib with trastuzumab deruxtecan and how well the combination works in treating patients with KRAS G12C mutated non-small cell lung cancer that has spread to nearby tissues or lymph nodes (locally advanced) or that has sprea…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California Davis Comprehensive Cancer Center, Sacramento, California

   Locations

   9 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07012031 on ClinicalTrials.gov

4. SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

   This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary si…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT07322341 on ClinicalTrials.gov

5. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

   This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain prot…

   Stage

   Phase 1

   Ages

   16 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT05269381 on ClinicalTrials.gov

6. GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

   This phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Run by

   Roswell Park Cancer Institute

   See if you can join NCT07017829 on ClinicalTrials.gov

7. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

   This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (lep…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Hospital in Arizona, Phoenix, Arizona

   Locations

   58 in total

   Run by

   NRG Oncology

   See if you can join NCT06500481 on ClinicalTrials.gov

8. Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

   This phase II clinical trial studies how well craniospinal irradiation (CSI) with hippocampal avoidance, using proton therapy or volumetric modulated arc therapy (VMAT), works in treating patients with breast cancer or non-small cell lung cancer (NSCLC) that has spread from the original (primary) t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   3 in total

   Run by

   University of Washington

   See if you can join NCT06518057 on ClinicalTrials.gov

9. A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

   This phase I trial studies the safety and side effects of a new positron emission tomography (PET) imaging agent called 64Cu-DOTA-pembrolizumab to see how well it works in determining treatment response for patients with stage IV non-small cell lung cancer (NSCLC) already receiving pembrolizumab. 6…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07619599 on ClinicalTrials.gov

10. PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

    This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer. Analyzing changes in PET/CT imaging scans may help doctors assess and pred…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT04151940 on ClinicalTrials.gov

11. Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

    This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or does not r…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT05098210 on ClinicalTrials.gov

12. SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

    This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has come back (recurrent). SX-682 is a drug that binds to receptors on some…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT05570825 on ClinicalTrials.gov

13. Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

    This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT07405086 on ClinicalTrials.gov

14. Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

    This phase I trial tests the safety, side effects, and best dose of carfilzomib in combination with sotorasib in treating patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    2 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06249282 on ClinicalTrials.gov

15. MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

    This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cel…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT04762199 on ClinicalTrials.gov

16. Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

    This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Arizona, Phoenix, Arizona

    Locations

    3 in total

    Run by

    Mayo Clinic

    See if you can join NCT06349642 on ClinicalTrials.gov

17. Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

    This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to o…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Dwight Owen

    See if you can join NCT06616623 on ClinicalTrials.gov

18. Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

    This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (primary site) to other places in the body (metastatic) on single agent immunotherapy. Diclofenac, a type of non-steroidal anti-inflammatory (…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Emory University Hospital Midtown, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT06731270 on ClinicalTrials.gov

19. PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of PBF-1129 in combination with nivolumab in treating patients with non-small cell lung cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as PBF-1129 and …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Dwight Owen

    See if you can join NCT05234307 on ClinicalTrials.gov

20. Insomnia in Patients With Metastatic Lung Cancer

    This study evaluates how common insomnia (difficulties with sleep) is in patients with lung cancer that has spread from where it first started (primary site) to other places in the body.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06472804 on ClinicalTrials.gov

21. Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

    This phase II trial tests how well craniospinal irradiation (CSI) using photon volumetric modulated arc radiotherapy (VMAT) works in treating patients with breast cancer or non-small cell lung cancer (NSCLC) that has spread from the original (primary) tumor to the cerebrospinal fluid and meninges (…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    2 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06910761 on ClinicalTrials.gov